Share Name Share Symbol Market Type Share ISIN Share Description
Bactiguard Holding Ab LSE:0QV2 London Ordinary Share SE0005878741 BACTIGUARD HOLDING ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 24.10 0.00 0.00 0.00 0.00 0.00 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Bactiguard's Urinary Catheters Approved for Reimbursement in the Dutch Market

10/09/2019 7:09am

PR Newswire (US)


Bactiguard Holding Ab (LSE:0QV2)
Historical Stock Chart

6 Months : From Aug 2019 to Feb 2020

Click Here for more Bactiguard Holding Ab Charts.

STOCKHOLM, Sept. 10, 2019 /PRNewswire/ -- Bactiguard's indwelling urinary catheters (Foleys) are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard's products for infection prevention and improve their quality of life.

To be able to sell medical devices to the Dutch home care providers in a broader scale, the products must be reimbursed. Bactiguard's Foleys are now included, which means that our partner in the Netherlands, Mediplast, can start to offer the products to a larger group of patients.

"The homecare market offers the biggest market potential for Foley catheters in the Netherlands. Now that our products are reimbursed, we will increase the pace of expansion in the country", says Jonas Östregård, SVP Sales & Marketing at Bactiguard.

"I am so pleased to be able to offer Bactiguard's infection preventive products to Dutch home care patients and thereby reduce the risk of hospital acquired infections and improve their quality of life. Now that the products are reimbursed, we can approach the homecare companies with a cost-effective solution for long term catheterized patients, which wasn't possible before," says Wil Graus, Sales and Managing Director at Mediplast Benelux.

Bactiguard and Mediplast have been partners since October 2018. The original agreement covered sales and distribution of Bactiguard's product portfolio for infection prevention (BIP) in Scandinavia. Already in December the same year, the partnership was extended to include Belgium, the Netherlands and Luxembourg.

Bactiguard's infection protection (BIP) solutions, which include products for the urinary tract, blood stream and respiratory tract, reduce the risk of healthcare associated infections, the use of antibiotics and thus the spread of multi-resistant bacteria. 

For further information, please contact:
Jonas Östregård
SVP Sales & Marketing
cell phone: +46-70-521-13-88

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-s-urinary-catheters-approved-for-reimbursement-in-the-dutch-market,c2899465

The following files are available for download:

https://mb.cision.com/Main/9686/2899465/1102960.pdf

190910 Bactiguard’s urinary catheters approved for reimbursement in the Dutch market

 

 

Copyright 2019 PR Newswire

1 Year Bactiguard Holding Ab Chart

1 Year Bactiguard Holding Ab Chart

1 Month Bactiguard Holding Ab Chart

1 Month Bactiguard Holding Ab Chart
Your Recent History
LSE
0QV2
Bactiguard..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200228 20:25:51